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Abstract 
 
Objectives: Patients prescribed clozapine were surveyed to assess (a) the effects, both positive and 
adverse, and overall satisfaction with clozapine in comparison to previously prescribed antipsychotics 
and (b) the relative significance of effects experienced, both positive and adverse, in terms of impact 
on subjective well-being.  
Methods: A total of 56 male patients prescribed clozapine at a forensic psychiatric hospital were 
surveyed using a 27-item questionnaire. All patients had been prescribed clozapine for a minimum of 
3 months. Respondents were asked to rate effects and satisfaction with clozapine treatment in 
comparison with previously prescribed antipsychotic medication on a five-point scale. Respondents 
were also asked to rate effects experienced with clozapine treatment in terms of impact on subjective 
well-being on a five-point scale.  
Results: A total of 89% of respondents reported greater satisfaction with clozapine than with 
previously prescribed antipsychotic medication. A majority of patients reported positive effects in 
terms of an improvement in their quality of life (68%) and social abilities (52%) with clozapine in 
comparison with previously prescribed antipsychotics. Nocturnal hypersalivation (84%) and weight 
gain (57%) were the most common adverse effects. Hedonic responses were assessed for each effect 
in order to determine the associated subjective experiences. The most positive hedonic responses 
were for quality of life, mood and alertness. In terms of adverse impact on subjective well-being, 
nocturnal hypersalivation ranked highest.  
Conclusions: Patients in a UK forensic sample are largely satisfied with clozapine treatment. The 
subjective effects of clozapine treatment should be taken into account by clinicians when assessing 
response. This may provide an opportunity to highlight the positive changes and prioritize 
management of the most undesirable adverse effects, which is likely to promote compliance and 
improve longer term treatment outcomes. 
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Introduction 
 
Clozapine is an atypical antipsychotic used in the treatment of resistant schizophrenia with an 
established efficacy superior to other antipsychotics [Wahlbeck et al. 1999]. Clozapine is associated 
with a range of side effects including those which are rare and life-threatening such as cardiomyopathy 
[Hagg et al. 2000], and others that are relatively common such as hypersalivation [Syed et al. 2008] 
and weight gain [Wirshing et al. 1999]. Discontinuation of clozapine is not uncommon in the first year 
[Ciapparelli et al. 2000], with a large proportion due to side effects experienced [Taylor et al. 2009]. 
Clinicians tend to place greater emphasis on adverse effects that are in fact of lesser importance to 
patients, such as the frequent blood tests required with clozapine treatment [Hodge and Jespersen, 
2008]. Additionally previous reports of the adverse effects of clozapine treatment have largely 
reported on their prevalence and not assessed the subjective importance attributed to them by 
patients [Angermeyer et al. 2001]. The aim of this survey was to assess patient satisfaction with 
clozapine in comparison with previous antipsychotics and patients’ experience of the side effects of 
clozapine treatment as well as its impact on subjective well-being. 
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Method 
 
The survey was undertaken at a forensic psychiatric hospital in the north-west of England. All patients 
prescribed a stable dose of clozapine for a minimum of 3 months were approached to take part in the 
survey. Of the 67 patients approached, 84% of patients agreed to participate in the survey and data 
were collected by medical staff who were part of the patient’s care team. The survey sample consisted 
of 56 men, with a mean age of 37.9 years [standard deviation (SD): 10.6, range: 22–59 years). A total 
of 42 respondents were White British, while the remainder included: 3 Other White; 3 White or Black 
Caribbean; 2 Black Caribbean; 2 Black African; 2 Pakistani; 1 Black or White African; and 1 Other Asian 
Background. The mean daily dose of clozapine was 349.3 mg (SD:  134.0 mg, range: 125–850 mg) and 
the mean length of prescription was 520.1 days (range: 93–2074 days).  
 
A 27-item questionnaire was used to assess subjective experiences with items adapted from a North 
American survey [Waserman and Criollo, 2000]. Respondents were asked to rate side effects and 
satisfaction with clozapine in comparison to previously prescribed antipsychotic medication on a five-
point scale (much worse, worse, no different, better, much better). We also asked respondents to rate 
the effects experienced in terms of hedonic response (how they felt about them) on a five-point scale 
(very unhappy about it, unhappy about it, don’t mind either way, happy about it, very happy about it). 
All data were gathered in accordance with the service evaluation standards of the responsible 
institutional review board (Research Governance Committee, Mersey Care NHS Trust). 
 
Results 
 
Respondents were largely positive about clozapine treatment: 86% of respondents reported that 
treatment with clozapine was better than treatment with previous antipsychotics and none thought 
it worse; 89% of respondents reported greater satisfaction with clozapine; and 96% reported better 
compliance with clozapine treatment than with previously prescribed antipsychotics. 
 
- Table 1 around here -  
 
Ratings of changes in side effects as a result of clozapine treatment are shown in Table 1. Responses 
revealed the most positive effects with clozapine treatment were in the domains of quality of life 
(mean: 3.93) and social abilities (mean: 3.59); 68% of patients (n = 38) reported their quality of life 
had improved and 52% of patients (n = 29) reported an improvement in their social abilities. A total of 
46% of respondents (n = 26) reported improvements in ‘thinking’ (a marker for cognitive ability) since 
starting clozapine treatment but 13% (n = 7) reported a deterioration in ‘thinking’. Similarly, 48% (n = 
27) reported improvements in sleep but 20% (n = 11) reported worse sleep than before. An 
improvement in mood was reported by 43% (n = 24) of the patients. 
 
Nocturnal hypersalivation was overwhelmingly the most frequently reported negative side effect, 
reported by 84% of patients (n = 47) (mean: 1.72); 57% of the patients (n = 32) also reported weight 
gain (mean: 2.29), 41% (n = 23) reported deterioration in daytime salivation and 39% reported an 
increase in constipation (n = 22). In addition, 27% of patients also reported a worsening of thirst (n = 
15). 
 
- Table 2 around here - 
 
To assess the subjective experience of effects associated with clozapine, hedonic responses were 
grouped into those patients for whom the effect had improved and those for whom it had 
deteriorated. The hedonic ratings were then averaged for each of the two groups. To maintain 
reliability of the ratings, only groups that included at least 20% of patients were included (see Table 
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2). Whilst many side effects deteriorated for many patients, the hedonic impact of this deterioration 
varied. For example, patients disliked the change in weight (mean hedonic rating: 1.81) more than 
they disliked the change in appetite (mean hedonic rating: 2.18). However, the most adverse impact 
on subjective well-being by far was deterioration in nocturnal salivation (mean hedonic rating: 1.72).  
 
Effects that improved as a result of clozapine treatment included a range of responses. For example, 
when patients perceived an improvement in quality of life, they reported being slightly happier about 
this (mean hedonic rating: 4.37) than about the improvement in energy levels (mean hedonic rating: 
4.14). Similarly, despite the fact that social abilities received the second highest mean change rating 
(mean change rating: 3.59), patients were as happy about this (mean hedonic rating: 4.24) as they 
were about the change in alertness (mean change rating: 3.14; mean hedonic rating: 4.31). 
 
Discussion 
 
We could not find any previous published survey that sought to explore the effects and overall 
satisfaction with clozapine and the relative significance of effects experienced, both positive and 
adverse, in terms of impact on subjective wellbeing. In this survey in a UK forensic mental health 
service, 86% of the respondents reported treatment with clozapine as very positive in comparison 
with previous medication and 68% of the patients reported improved quality of life.  
 
These are important findings for clinicians within a forensic setting, particularly where there has been 
a delay in commencing clozapine [Howes et al. 2012] and our findings are similar to a survey in a non-
forensic sample [Taylor et al. 2000]. In our survey, nocturnal hypersalivation was the most commonly 
experienced adverse effect and this is consistent with a previous survey of the prevalence of adverse 
effects in North America [Waserman and Criollo, 2000].  
 
The added contribution that our survey makes is in asking respondents about the associated 
significance attached to each side effect; responses indicated clear differences in terms of impact on 
subjective well-being. For example, nocturnal hypersalivation was the most distressing side effect 
experienced by our sample of patients followed by weight gain. In terms of positive effects when 
patients perceived an improvement in quality of life, they reported being slightly happier about this 
than about the improvement in energy levels.  
 
Patients also attributed a large subjective significance to improvement in mood. Patients’ subjective 
experiences of medication are important and it is recognized that these are powerful predictors of 
adherence [Fujikawa et al. 2008], which in turn influences treatment outcomes [Hellewell, 2002]. 
However, many patients with a diagnosis of schizophrenia discontinue their medication in the first few 
years, citing their experience of side effects as a crucial aspect of their decision [Kampman and 
Lehtinen, 1999]. We suggest that clinicians should be aware of the relative impact of different side 
effects. Several instruments have been developed to evaluate perceived side effects of antipsychotic 
treatment: Medication and Adherence Rating Scale [Thompson et al. 2000]; Self-rating Scale to 
Measure Subjective Well-being under Neuroleptic Treatment [Naber, 1995]; and Patient Assessment 
Questionnaire [Mojtabai et al. 2012]. We are not aware of these being used in routine clinical practice 
and it might be worth exploring the use of such instruments whilst patients wait in clozapine clinics 
and the responses discussed at subsequent clinical reviews. 
 
This was a survey of patients established on clozapine therapy with a minimum duration of treatment 
of 93 days and mean duration of 520 days, indicating the sample is positively biased in favour of 
clozapine therapy. Additionally, the relatively small number of respondents in this survey may not be 
representative of patients in other forensic services. However, we had an encouraging response rate 
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and our population of a broad ethnic mix of patients, although exclusively male, is unlikely to be 
significantly different from other male forensic populations.  
 
In conclusion, clinicians should routinely explore not only the presence of effects of clozapine 
treatment, both positive and negative, but also their subjective importance in terms of impact on well-
being. This may provide an opportunity to highlight the positive changes and to prioritize management 
of the most undesirable adverse effects, which is likely to promote adherence to medications and 
improve longer term treatment outcomes. 
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Table 1. Subjective experiences of side effects: ratings of clozapine treatment compared with previous 
antipsychotic treatment (n = 56). 
 
 Number of responses  
After starting clozapine, 
did the following change? 
 
Much 
worse [1] 
Worse  
[2] 
No 
different  
[3] 
Better [4] Much 
better [5] 
Mean 
rating 
Nocturnal salivation 26 21 7 2 0 1.72 
Weight 14 18 19 4 1 2.29 
Daytime salivation 7 16 33 0 0 2.46 
Constipation 7 15 30 4 0 2.55 
Thirst 1 14 39 2 0 2.75 
Dry mouth 4 9 40 1 2 2.79 
Itchiness 1 10 45 0 0 2.79 
Unusual movements 2 10 42 2 0 2.79 
Sweating 1 8 47 0 0 2.82 
Dizziness 0 11 43 2 0 2.84 
Wetting yourself–night 2 7 46 0 1 2.84 
Vision 1 9 43 2 1 2.88 
Abdominal pain 1 5 49 1 0 2.89 
Breathing 1 7 45 2 1 2.91 
Energy levels 1 20 21 11 3 2.91 
Headache 2 1 52 1 0 2.93 
Unusual sensations 1 5 48 1 1 2.93 
Urination 0 6 48 1 1 2.95 
Wetting yourself - day 0 1 54 0 1 3.02 
Alertness 1 7 32 15 1 3.14 
Activity level 0 10 26 16 4 3.25 
Appetite 0 11 22 17 6 3.32 
Sleep 2 9 18 21 6 3.36 
Mood 0 5 27 16 8 3.48 
Thinking 1 6 23 12 14 3.57 
Social life 1 1 25 22 7 3.59 
Quality of life 0 2 16 22 16 3.93 
Note: Change ratings were on a 5-point scale where 1 = ‘much worse than before’ and 5 = ‘much better 
than before’. 
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Table 2. Mean hedonic ratings of side effects with clozapine treatment grouped by deterioration and 
improvement (n = 56). 
 
Effects that deteriorated for 20% or more of patients  Effects that improved for 20% or more of patients 
 mean hedonic 
rating 
% patients 
(n) 
  mean hedonic 
rating 
% patients 
(n) 
Nocturnal salivation 1.72 84% (47)  Quality of life 4.37 68% (38) 
Weight gain 1.81 57% (32)  Activity level 4.35 36% (20) 
Daytime salivation 1.83 41% (23)  Alertness 4.31 29% (16) 
Constipation 1.86 39% (22)  Social life 4.24 52% (29) 
Unusual movement 2.00 21% (12)  Mood 4.21 43% (24) 
Energy 2.14 38% (21)  Thinking 4.19 46% (26) 
Dry mouth 2.15 23% (13)  Energy levels 4.14 25% (14) 
Appetite 2.18 20% (11)  Sleep 4.07 48% (27) 
Itchiness 2.27 20% (11)     
Sleep 2.27 20% (11)     
Thirst 2.40 27% (15)     
Appetite 2.87 41% (23)     
Note: Feelings rated on a 5-point scale: 1 = very unhappy about it; 2 = unhappy about it; 3 = don’t 
mind either way; 4 = happy about it; 5 = very happy about it. 
